Navigation Links
Circassia Announces Successful Results From Phase II Clinical Study of ToleroMune(R) Cat Allergy Therapy
Date:11/20/2009

f development for our cat allergy therapy, and will prove invaluable as we progress our broader portfolio of ToleroMune products," said Steve Harris , Circassia's CEO. "We are particularly pleased that the ToleroMune treatment achieved such a marked improvement in ocular symptoms, which can be a particular problem in cat allergy. As well as benefiting patients, this effect scientifically validates the ToleroMune approach and its novel focus on generating regulatory T cells to shut down this type of IgE-mediated allergic response."

About Circassia

Circassia is a specialty biopharmaceutical company focused on the field of allergy. The company's range of allergy therapeutics utilises its proprietary T-cell epitope desensitisation technology, ToleroMune, in a short treatment regime without the need for adjuvants or other immune stimulators. Circassia's products offer potential major clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year.

ToleroMune technology has additional potential regulatory and supply chain benefits. The short peptides utilised in Circassia's products are manufactured chemically, in contrast to existing allergen immunotherapies, which are purified from natural sources. Circassia's approach applies the chemistry, manufacturing and control standards associated with conventional pharmaceuticals to immunotherapy. This fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, and requiring elimination of the batch-to-batch potency variability that is an intrinsic feature of many currrent treatments.

Circassia has a highly experienced management team with a proven track record in product development
'/>"/>

SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. IVF Florida Announces New Patient Finance Solution for Fertility Treatments
2. Secretary Shinseki Announces Study of Vietnam-Era Women Veterans
3. Great Customer Service Just Got Better as Emedco Announces the Launch of their Completely Updated and Enhanced Website
4. Nationwide Imaging Services, Inc., Leader In Diagnostic Imaging Equipment, Announces The Creation Of New Business Division Nationwide Medical Equipment Services
5. Parascript Announces AccuDetect 3.0 Computer Aided Detection (CAD) Algorithms With Improved Performance for CAD Vendors and Manufacturers of Mammography Systems
6. Universal Health Services, Inc. Announces Stock Split and Cash Dividend Increase
7. GettingHired Announces Additional Funding for Continued Growth as Well as R&D of New Product for Long Term Disability and Workers Comp.
8. Ziosoft Announces the Appointment of Rob Royea, Vice President, Sales and Marketing
9. WAT-AAH!, The First Functional Bottled Water For Kids, Announces The Release of WATs-THE-WORD?!
10. Oncolytics Biotech(R) Inc. Announces Terms of Unit Offering
11. Albireo Announces Positive Clinical Data on A3309 in Patients with Chronic Idiopathic Constipation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... first year follow a set of predictable steps ... first words. However, previous research had not addressed ... hearing and deaf infants. Now, University of Missouri ... by infants, ability to hear their own babbling. ... cochlear implants to help correct their hearing soon ...
(Date:9/23/2014)... PITTSBURGH, PA (PRWEB) September 23, 2014 "The ... and infection control," said an inventor from Sacramento, Ca.. "Call ... patient bedding or left hanging on the IV pole out ... patients have the nurse call device whenever they need it, ... CADDY to effectively position the nurse call device within easy ...
(Date:9/23/2014)... CONVENE PATHWAYS TO PREVENTION WORKSHOP: ROLE OF OPIOIDS IN ... , The National Institutes of Health is convening a ... evidence on the long-term effectiveness and potential risks of ... the nation,s top experts in the field of pain ... as key NIH scientists who focus on pain related ...
(Date:9/23/2014)... September 23, 2014 World of Home ... philanthropic support. Most recently, the gym has been raising ... Fitness program. Throughout the year, World of Home Fitness ... charitable causes. , Over the summer, World of Home ... Through their Ageless Fitness program, participants helped feed seniors ...
(Date:9/23/2014)... San Diego, CA (PRWEB) September 23, 2014 ... website daily regarding all the latest information from the ... announced on September 5, that its Private Label Jalapeno ... glass and small stones. Publix Jalapeno Bagels ... in the bakery department. , Taking into consideration ...
Breaking Medicine News(10 mins):Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:World of Home Fitness Supports Meals on Wheels 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... Aug. 31 Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that ... Sept. 10, 2009, at 2:40 p.m. EDT. Alan Levin, Chief Financial Officer ... The presentation will be webcast live and can be accessed from ... , , About Endo , ...
... , , BERWYN, Pa., Aug. 31 ... service multinational clinical research organization (CRO) conducting studies in over 30 ... today announced that on August 25, 2009, it received a letter ... its Form 10-Q for the period ended June 30, 2009, NASDAQ ...
... , , SCOTTSDALE, ... today announced that, at the Company,s 2009 Annual Meeting of Stockholders, ... an overwhelming majority all of the Company,s nominees to the board ... 63,725,589, representing approximately 56% of the 114,007,240 shares outstanding as of ...
... study, blood-thinning drug best for those at highest risk of ... patients, or those with a prior history of stroke, are ... treat atrial fibrillation, a common heart rhythm disorder, a new ... also say the drug is especially beneficial for patients with ...
... Aug. 31 (HealthDay News) -- Walk-in retail clinics staffed by ... study has found. , Writing in the Sept. 1 issue ... Dr. Ateev Mehrotra said that retail clinics -- which are ... and other retail chain stores such as Target and Wal-Mart ...
... patients choose where to get their care based on how ... at Fox Chase Cancer Center have recently documented a growing ... at high volume centers, which are generally located in metropolitan ... a study published in the Journal of Clinical Oncology ...
Cached Medicine News:Health News:Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 2Health News:Encorium Receives NASDAQ Deficiency Letter Regarding Stockholders' Equity 2Health News:Encorium Receives NASDAQ Deficiency Letter Regarding Stockholders' Equity 3Health News:Healthcare Trust of America, Inc. Announces Results of 2009 Annual Meeting of Stockholders 2Health News:Healthcare Trust of America, Inc. Announces Results of 2009 Annual Meeting of Stockholders 3Health News:Oldest Heart Patients May Get Most From Warfarin 2Health News:Retail Medical Clinics Offer Quality Care: Study 2Health News:Retail Medical Clinics Offer Quality Care: Study 3Health News:Does the distance a patient has to travel affect where they choose to get their care? 2
(Date:9/23/2014)... , Sept. 23, 2014  SiteOne Therapeutics Inc. ... equity financing. Led by Sears Capital Management and Biobrit ... Joe Zakrzewski , the $1.5 million financing positions SiteOne ... for pain and to further develop its technology platform ... indications. In conjunction with the financing, ...
(Date:9/23/2014)...   COTA, Inc. today announced it has ... A funding round led by Horizon Healthcare Services, Inc. ... big data platform designed by practicing oncologists to deliver ... care in support of healthcare,s new value-based reimbursement model. ... of the COTA platform, hire biostatisticians, outcome analysts, data ...
(Date:9/23/2014)... , Sept. 23, 2014  While proton therapy recently began in the ... Ashya King , another case in the United States ... a young boy who was given just days to live now looks ... Logan Green of Arizona complained of a ... of medical treatments that will conclude Sept. 23, when he completes ...
Breaking Medicine Technology:SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 45-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 25-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 35-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 4
... Pervasis Therapeutics, Inc. today announced that it has ... government,s Qualifying Therapeutic Discovery Project, which provides tax credits ... produce new therapies, reduce long-term health care costs, or ... next 30 years.   Pervasis is a ...
... 4, 2010 The physicians of Westside Medical Associates ... Beverly Hills , California have announced the results of a ... CT scans save lives.  According to Drs. Norman ... Medical Imaging, this study should once and for all settle ...
Cached Medicine Technology:Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project 2Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project 3Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project 4Annual CT Lung Screening Saves Lives 2
... Screen ELISA test system is a qualitative screening ... human sera. When performed according to the directional ... all ANAs commonly tested for, such as those ... SSA, SSB, and Scl-70. The test is also ...
... Immuno Concepts manufactures slides that are compatible ... to decrease the number of pipetting steps ... sample dilutions on the slides. Ask Immuno ... and these slides. These slide formats are ...
... patented HEp-2 cell line that has been ... SS-A/Ro autoantibodies, without affecting the other ANA ... published worldwide on the HEp-2000 ANA substrate, ... when used in place of standard HEp-2 ...
... ENA assays can be used to ... antibodies, which are associated with various ... lupus erythematosus (Lupus), Sjgren's syndrome, mixed ... scleroderma, polymyositis, dermatomyositis, and Raynaud's phenomenon. ...
Medicine Products: